Dexrazoxane
- Generic Name
- Dexrazoxane
- Brand Names
- Savene, Totect, Zinecard
- Drug Type
- Small Molecule
- Chemical Formula
- C11H16N4O4
- CAS Number
- 24584-09-6
- Unique Ingredient Identifier
- 048L81261F
- Background
An antimitotic agent with immunosuppressive properties. Dexrazoxane, the (+)-enantiomorph of razoxane, provides cardioprotection against anthracycline toxicity. It appears to inhibit formation of a toxic iron-anthracycline complex. [PubChem]
...
- Indication
For reducing the incidence and severity of cardiomyopathy associated with doxorubicin administration in women with metastatic breast cancer who have received a cumulative doxorubicin hydrochloride dose of 300 mg/m^2 and would benefit from continued doxorubicin therapy. Also approved for the treatment of extravasation from intravenous anthracyclines.
- Associated Conditions
- Doxorubicin Induced Cardiomyopathy, Drug Extravasation
- Associated Therapies
- -
Testing a Standardized Approach to Surgery and Chemotherapy for Type I Pleuropulmonary Blastoma or the Addition of an Anti-cancer Drug, Topotecan, to the Usual Treatment for Types II and III Pleuropulmonary Blastoma
- Conditions
- Interventions
- Procedure: Biospecimen CollectionOther: Patient ObservationProcedure: Computed TomographyProcedure: Bone ScanDrug: CyclophosphamideBiological: DactinomycinProcedure: ResectionProcedure: Ultrasound ImagingDrug: DexrazoxaneDrug: VincristineDrug: DoxorubicinProcedure: EchocardiographyDrug: IfosfamideProcedure: Magnetic Resonance ImagingProcedure: Multigated Acquisition ScanProcedure: Positron Emission TomographyDrug: Topotecan
- First Posted Date
- 2024-10-18
- Last Posted Date
- 2024-12-05
- Lead Sponsor
- Children's Oncology Group
- Target Recruit Count
- 110
- Registration Number
- NCT06647953
CHIP-AML22/Quizartinib: Quizartinib + Chemotherapy in Newly Diagnosed Pediatric FLT3-ITD+ and NPM1wt AML Patients
- First Posted Date
- 2024-02-16
- Last Posted Date
- 2024-02-16
- Lead Sponsor
- Princess Maxima Center for Pediatric Oncology
- Target Recruit Count
- 60
- Registration Number
- NCT06262438
- Locations
- 🇳🇱
Princess Máxima Center for pediatric oncology, Utrecht, Netherlands
Prevention of Anthracycline-Induced Cardiac Dysfunction With Dexrazoxane in Patients With Diffuse Large-B Cell Lymphoma
- First Posted Date
- 2024-01-23
- Last Posted Date
- 2024-08-19
- Target Recruit Count
- 324
- Registration Number
- NCT06220032
- Locations
- 🇳🇱
NL-Breda-AMPHIA, Breda, Netherlands
🇳🇱NL-Almelo-ZGTALMELO, Almelo, Netherlands
🇳🇱NL-Amstelveen-AMSTELLAND, Amstelveen, Netherlands
Venetoclax Basket Trial for High Risk Hematologic Malignancies
- Conditions
- Myelodysplastic Syndromes, SecondaryMyelodysplastic Syndromes, Previously TreatedTreatment-Related Acute Myeloid LeukemiaTherapy-Related Myelodysplastic SyndromeAcute Lymphoblastic Leukemia With Failed RemissionMyelodysplastic Syndromes, de NovoLymphoblastic Lymphoma, in RelapseAcute Leukemia of Ambiguous Lineage in RelapseLymphoblastic Lymphoma, RefractoryAcute Leukemia of Ambiguous Lineage
- Interventions
- First Posted Date
- 2022-03-23
- Last Posted Date
- 2024-04-02
- Lead Sponsor
- Andrew E. Place, MD
- Target Recruit Count
- 92
- Registration Number
- NCT05292664
- Locations
- 🇺🇸
University of California San Francisco-Benioff Children's Hospital, San Francisco, California, United States
🇺🇸Dana-Farber Cancer Institute, Boston, Massachusetts, United States
Use of the Cardioprotectant Dexrazoxane During Congenital Heart Surgery
- First Posted Date
- 2021-08-09
- Last Posted Date
- 2021-08-09
- Lead Sponsor
- University of Texas at Austin
- Target Recruit Count
- 12
- Registration Number
- NCT04997291
- Locations
- 🇺🇸
Dell Children's Medical Center of Central Texas, Austin, Texas, United States
Prevention of Heart Failure Induced by Doxorubicin With Early Administration of Dexrazoxane
- First Posted Date
- 2019-04-29
- Last Posted Date
- 2024-11-18
- Lead Sponsor
- University of Arkansas
- Target Recruit Count
- 25
- Registration Number
- NCT03930680
- Locations
- 🇺🇸
University of Arkansas for Medical Sciences, Little Rock, Arkansas, United States
Dinutuximab, Sargramostim, and Combination Chemotherapy in Treating Patients With Newly Diagnosed High-Risk Neuroblastoma
- Conditions
- Interventions
- Procedure: Autologous Hematopoietic Stem Cell TransplantationDrug: CarboplatinDrug: CisplatinDrug: CyclophosphamideDrug: DexrazoxaneBiological: DinutuximabDrug: DoxorubicinDrug: EtoposideRadiation: External Beam Radiation TherapyDrug: IsotretinoinDrug: MelphalanBiological: SargramostimDrug: ThiotepaDrug: TopotecanDrug: Vincristine
- First Posted Date
- 2018-12-26
- Last Posted Date
- 2024-10-17
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 42
- Registration Number
- NCT03786783
- Locations
- 🇺🇸
Saint Jude Children's Research Hospital, Memphis, Tennessee, United States
🇳🇿Starship Children's Hospital, Grafton, Auckland, New Zealand
🇦🇺The Children's Hospital at Westmead, Westmead, New South Wales, Australia
OlaReDo - Olaratumab and Rechallenge With Doxorubicin in Soft Tissue Sarcoma Patients
- Conditions
- Interventions
- First Posted Date
- 2018-10-05
- Last Posted Date
- 2020-07-15
- Target Recruit Count
- 2
- Registration Number
- NCT03698227
- Locations
- 🇩🇪
Medizinische Fakultät Carl Gustav Carus Medizinische Klinik I Internistische Onkologie, Dresden, Germany
🇩🇪Helios Klinikum Bad Saarow, Bad Saarow, Germany
🇩🇪Helios Klinikum Berlin-Buch Klinik für Onkologie und Palliativmedizin, Berlin, Germany
A Trial of Epigenetic Priming in Patients With Newly Diagnosed Acute Myeloid Leukemia
- Conditions
- Interventions
- Drug: AzacitidineDrug: DecitabineDrug: CytarabineDrug: DaunorubicinDrug: EtoposideCombination Product: ITMHADrug: IdarubicinDrug: FludarabineDrug: MitoxantroneDrug: SorafenibDrug: Erwinia asparaginaseDrug: G-CSFDrug: DexrazoxaneDrug: Asparaginase Erwinia Chrysanthemi, Recombinant-RywnBiological: Stem Cell Transplant
- First Posted Date
- 2017-05-23
- Last Posted Date
- 2024-05-29
- Lead Sponsor
- St. Jude Children's Research Hospital
- Target Recruit Count
- 206
- Registration Number
- NCT03164057
- Locations
- 🇺🇸
Rady Children's Hospital and Health Center, San Diego, California, United States
🇺🇸Children's Hospital of Central California, Madera, California, United States
🇺🇸Children's Hospital of Orange County, Orange, California, United States
Treatment of Newly Diagnosed Acute Lymphoblastic Leukemia in Children and Adolescents
- Conditions
- Interventions
- First Posted Date
- 2017-01-13
- Last Posted Date
- 2024-08-15
- Lead Sponsor
- Dana-Farber Cancer Institute
- Target Recruit Count
- 560
- Registration Number
- NCT03020030
- Locations
- 🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸Rutgers Cancer Institute of New Jersey, New Brunswick, New Jersey, United States
🇨🇦Hospital Sainte Justine, University of Montreal, Montreal, Quebec, Canada
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.